EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report

Baohua Chen, Yuanyuan Jia, Lingjun Meng, Nanjun Hu

Frontiers in Oncology · 27.03.2026 · 16

DOI: 10.3389/fonc.2026.1764908 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 27.03.2026. Verfasst von Baohua Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer, a prevalent malignancy among women, is primarily categorized into four subtypes based on immunohistochemistry: luminal A breast cancer, luminal B breast cancer, HER2-enriched breast cancer, and triple-negative breast cancer (TNBC). Molecular targets for TNBC therapy are lacking, and TNBC is characterized by a high risk of recurrence and a poor prognosis. The advent of immune checkpoint inhibitors (ICIs), including PD-1, PD-L1, and CTLA-4 inhibitors, has led to therapeutic advances in the management of TNBC. The combination of chemotherapy and immunotherapy has been shown to improve patient outcomes and survival rates. This case primarily discusses immunotherapy combination treatments for PD-L1-negative TNBC patients, for which research remains relatively scarce. This case report focuses on a 48-year-old female patient with PD-L1-negative stage IV TNBC who exhibited a significant therapeutic response to cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy, achieving a partial response (PR), as assessed by clinical evaluation. The tumor volume was reduced by more than 75%. The patient experienced grade 3 neutropenia, grade 2 thrombocytopenia, grade 2 nausea, and grade 2 immune-related adverse events, including pruritus and hyperthyroidism. Furthermore, this report reviews the current principal treatment modalities for TNBC. Particular emphasis was placed on discussing immunotherapy combination treatments for TNBC. Additional studies with larger cohorts are warranted for comprehensive translational research on PD-L1-negative TNBC, aiming to validate the efficacy and elucidate the mechanisms of action of various ICIs. This case highlights that dual-targeted therapy may provide a promising therapeutic option for patients with PD-L1-negative TNBC.

Schlagwörter

Stichwörter der Autor:innen

CTLA-4PD-1cadonilimabimmunotherapytriple-negative breast cancer (TNBC)

Autor:innen und Institutionen

  • 2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.

Zitieren

APA

Chen, B., Jia, Y., Meng, L., & Hu, N. (2026). PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1764908

Vancouver

Chen B, Jia Y, Meng L, Hu N. PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1764908

BibTeX
@article{Chen2026,
  author = {Chen, Baohua and Jia, Yuanyuan and Meng, Lingjun and Hu, Nanjun},
  title = {PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1764908}
}
Kostenlos starten →